#ISICEM21: COV-BARRIER Study - Baricitinib for COVID-19
- ICU
- 03/09/2021
A study was conducted to evaluate the efficacy and safety of baricitinib, an oral selective Janus kinase 1/2 inhibitor, in combination with standard of care for the treatment of hospitalised patients
READ MORE